Comparative Pharmacology
Head-to-head clinical analysis: GILDESS FE 1 5 30 versus MICROGESTIN FE 1 20.
Peer-Reviewed Evidence
Head-to-head clinical analysis: GILDESS FE 1 5 30 versus MICROGESTIN FE 1 20.
GILDESS FE 1.5/30 vs MICROGESTIN FE 1/20
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive: ethinyl estradiol (estrogen) and levonorgestrel (progestin) suppress gonadotropin secretion (FSH and LH) via negative feedback, inhibiting ovulation, increasing cervical mucus viscosity, and altering endometrial receptivity.
Combination oral contraceptive containing ethinyl estradiol (estrogen) and norethindrone acetate (progestin). Suppresses gonadotropins via negative feedback on hypothalamic-pituitary axis, inhibiting ovulation; increases cervical mucus viscosity and alters endometrial lining.
One tablet orally once daily at the same time each day for 21 consecutive days, followed by 7 days of placebo tablets.
One tablet orally once daily, containing norethindrone acetate 1 mg and ethinyl estradiol 20 mcg, taken at the same time each day for 21 days followed by 7 days of placebo (iron tablets) or continuous cycling per prescribing information.
None Documented
None Documented
Ethinyl estradiol: terminal elimination half-life approximately 13-27 hours (mean ~17 hours); clinical context: supports daily dosing with steady state achieved in ~1 week. Gestodene: terminal elimination half-life approximately 12-15 hours; clinical context: allows for maintaining stable serum concentrations with once-daily dosing.
Norethindrone: 5-14 hours (mean 8 hours); Ethinyl estradiol: 12-24 hours (mean 18 hours); Steady-state in 5-7 days
Ethinyl estradiol (EE) is primarily excreted in urine (40-45%) and feces (40-45%) as glucuronide and sulfate conjugates; less than 8% is excreted unchanged. Gestodene is extensively metabolized; its metabolites are excreted in urine (50-60%) and feces (30-40%), with less than 1% unchanged.
Renal: ~50-60% as metabolites; Fecal: ~30-40% as metabolites; Biliary: minor; <1% unchanged
Category C
Category C
Oral Contraceptive
Oral Contraceptive